In Vivo Antitumor Activity of SU11248, a Novel Tyrosine Kinase Inhibitor Targeting Vascular Endothelial Growth Factor and Platelet-derived Growth …
…, TJ Ngai, LB Lee, LJ Murray, J Carver, E Chan… - Clinical cancer …, 2003 - AACR
One challenging aspect in the clinical development of molecularly targeted therapies, which
represent a new and promising approach to treating cancers, has been the identification of …
represent a new and promising approach to treating cancers, has been the identification of …
[HTML][HTML] Vemurafenib in Multiple Nonmelanoma Cancers with BRAF V600 Mutations
…, RD Hofheinz, M Hidalgo, E Chan… - … England Journal of …, 2015 - Mass Medical Soc
Background BRAF V600 mutations occur in various nonmelanoma cancers. We undertook
a histology-independent phase 2 “basket” study of vemurafenib in BRAF V600 mutation–…
a histology-independent phase 2 “basket” study of vemurafenib in BRAF V600 mutation–…
[HTML][HTML] Cetuximab-induced anaphylaxis and IgE specific for galactose-α-1, 3-galactose
Background Cetuximab, a chimeric mouse–human IgG1 monoclonal antibody against the
epidermal growth factor receptor, is approved for use in colorectal cancer and squamous-cell …
epidermal growth factor receptor, is approved for use in colorectal cancer and squamous-cell …
Widespread potential for growth-factor-driven resistance to anticancer kinase inhibitors
…, J Fridlyand, Y Yan, E Penuel, L Burton, E Chan… - Nature, 2012 - nature.com
Mutationally activated kinases define a clinically validated class of targets for cancer drug
therapy 1 . However, the efficacy of kinase inhibitors in patients whose tumours harbour such …
therapy 1 . However, the efficacy of kinase inhibitors in patients whose tumours harbour such …
Intention of nurses to accept coronavirus disease 2019 vaccination and change of intention to accept seasonal influenza vaccination during the coronavirus disease …
Background Maintaining health of healthcare workers with vaccination is a major component
of pandemic preparedness and acceptance of vaccinations is essential to its success. This …
of pandemic preparedness and acceptance of vaccinations is essential to its success. This …
Colon cancer, version 1.2017, NCCN clinical practice guidelines in oncology
AB Benson, AP Venook, L Cederquist, E Chan… - Journal of the National …, 2017 - jnccn.org
This portion of the NCCN Guidelines for Colon Cancer focuses on the use of systemic
therapy in metastatic disease. Considerations for treatment selection among 32 different …
therapy in metastatic disease. Considerations for treatment selection among 32 different …
Nivolumab monotherapy in recurrent metastatic urothelial carcinoma (CheckMate 032): a multicentre, open-label, two-stage, multi-arm, phase 1/2 trial
…, F de Braud, M Morse, DT Le, D Jaeger, E Chan… - The lancet …, 2016 - thelancet.com
Background Few effective treatments exist for patients with advanced urothelial carcinoma
that has progressed after platinum-based chemotherapy. We assessed the activity and safety …
that has progressed after platinum-based chemotherapy. We assessed the activity and safety …
[HTML][HTML] Phase II pilot study of vemurafenib in patients with metastatic BRAF-mutated colorectal cancer
Purpose BRAF V600E mutation is seen in 5% to 8% of patients with metastatic colorectal
cancer (CRC) and is associated with poor prognosis. Vemurafenib, an oral BRAF V600 inhibitor…
cancer (CRC) and is associated with poor prognosis. Vemurafenib, an oral BRAF V600 inhibitor…
Hypoxia-inducible factor determines sensitivity to inhibitors of mTOR in kidney cancer
…, C Tran, IK Mellinghoff, DS Welsbie, E Chan… - Nature medicine, 2006 - nature.com
Inhibitors of the kinase mammalian target of rapamycin (mTOR) have shown sporadic activity
in cancer trials, leading to confusion about the appropriate clinical setting for their use. …
in cancer trials, leading to confusion about the appropriate clinical setting for their use. …
Sotorasib plus Panitumumab in Refractory Colorectal Cancer with Mutated KRAS G12C
…, D Cunningham, KH Yeh, E Chan… - … England Journal of …, 2023 - Mass Medical Soc
Background KRAS G12C is a mutation that occurs in approximately 3 to 4% of patients with
metastatic colorectal cancer. Monotherapy with KRAS G12C inhibitors has yielded only …
metastatic colorectal cancer. Monotherapy with KRAS G12C inhibitors has yielded only …